MediQuest Announces Sale of Late Stage Onychomycosis Program to EFFELL LLC, Fir...
`
`Page 1 of 4
`
`PRWeb
`
`HOME
`
`NEWS CENTER
`
`BLOG
`
`Tuesday, May 24, 2016
`
`LOGIN
`
`CREATE A FREE ACCOUNT
`
`  
`
`MediQuest Announces Sale of Late Stage
`Onychomycosis Program to EFFELL LLC, First in
`a Series of Asset Sales
`
`Share Article
`
`    
`
`MediQuest Therapeutics announces the sale of late stage Onychomycosis/Onycholysis programs
`to EFFELL LLC, the first in a series of asset sales.
`
`SEATTLE, WA (PRWEB) SEPTEMBER 19, 2012
`
`MediQuest Therapeutics today announced that EFFELL LLC, a Delaware Limited Liability
`Company has acquired the rights to MediQuest’s Onychomycosis and Onycholysis clinical
`programs. This is the first sale in a series of asset sales MediQuest is conducting through a
`receivership established to monetize the company’s clinical programs for the benefit of
`creditors and shareholders. Treating toe appearance topically (non-systemically) is believed to
`be a multi-billion dollar business worldwide. MediQuest has developed proprietary topical
`treatments that combine known effective and safe doses of anti-fungals with MediQuest’s
`patented Topical AmphiMatrix gel (TAM) to thickened nails and skin for the treatment of
`Onychomycosis and/or Onycholysis. Terms of the deal were not disclosed; however milestone
`payments and royalties typical to biotech transactions of this nature are included.
`
`Dr. Fred Dechow, MediQuest CEO commented: “We are pleased that our derm platform has
`been validated through the purchase of the Onycho program by EFFELL. Their expertise in
`marketing this topical formulation will benefit those who suffer from unsightly toes and who are
`not willing to take systemic risk by using the oral drugs on the market currently. MediQuest will
`be selling/licensing its remaining assets (Raynaud’s Syndrome, Skin Lighteners and TAM
`formulation) in a similar fashion for the benefit of our creditors and company Shareholders.”
`
`About EFFELL LLC
`The buyer, EFFELL, LLC, is a Delaware LLC established for the purpose of commercializing the
`
`http://www.prweb.com/releases/2012/9/prweb9911525.htm
`
`5/24/2016
`
`CFAD v. Anacor, IPR2015-01776 ANACOR EX. 2175 - 1/4
`
`

`
`MediQuest Announces Sale of Late Stage Onychomycosis Program to EFFELL LLC, Fir...
`
`Page 2 of 4
`
`MediQuest Onycho Patent Rights and Technology in the treatment of fungal diseases, including
`the treatment of Onychomycosis and Onycholysis and the improvement of nail appearance.
`EFFELL has acquired all proprietary processes, trade secrets, technical information and know-
`how, including, clinical studies, clinical records, compositions, formulations, economic and
`market information from MediQuest to make, use, or offer for sale the licensed products in the
`Onychomycosis and or Onycholysis field of use which are owned or controlled by MediQuest.
`EFFELL was represented by DLA Piper http://www.dlapiper.com Lisa A. Haile, J.D., Ph.D. lisa
`(dot)haile(at)dlapiper(dot)com (San Diego), in the transaction.
`
`EFFELL LLC Contact
`For more information about the EFFELL transaction contact; John Glazer glazerjohnm(at)gmail
`(dot)com.
`
`About MediQuest Therapeutics, Inc. MediQuest Therapeutics is a Washington state based
`specialty pharmaceutical company using its proprietary topical delivery system in late-stage
`clinical trials targeting infectious and inflammatory skin diseases and conditions. The
`Company's major efforts have been focused on projects targeting Onychomycosis,
`Onycholysis, Raynaud's phenomenon (Vascana, a Phase III drug), nail psoriasis and actinic
`keratosis. MediQuest also has a validated skin lightener product. Its TAM formulation can be
`combined with other known safe drugs for topical treatments in many other areas. In August
`2012, MediQuest assigned its assets for the benefit of creditors to Miles Stover, Court
`Appointed Receiver. The sale of the Onycho program to EFFELL is the first in the disposition of
`MediQuests assets. MediQuest was represented by K&L Gates http://www.klgates.com
`(Seattle), Gary Kocher gary(dot)kocher(at)klgates(dot)com, lead counsel in the sale of Onycho.
`
`MediQuest Contacts: For more information about the EFFELL transaction or the remaining
`assets for sale, contact Dr. Fred Dechow, MediQuest CEO and Director ((417) 683-1201)
`frederick_j_dechow(at)yahoo(dot)com or Joe Piper, Managing Director Point B Capital jpiper(at)
`pointbcap(dot)com (206.832.1992), or Terry McGovern ((949) 632-4214), Numoda Capital
`tmcgovern(at)numodacapital(dot)com.
`
`For questions about the receivership, contact either Joe Piper or Miles Stover (253.209.9183)
`mstover(at)turnaround-inc(dot)com
`
`Remaining MediQuest assets for sale include:
`1.    TAM PLATFORM: TAM delivery technology patent and patent applications cover the 30% to
`65% water composition range where various therapeutic agents can be delivered safely and
`effectively. Lacquers and ointments typically have less than 10% water content, while water
`comprises over 80% of creams, lotions foams, and gels. Any composition outside of the 30% to
`65% water composition range fails to deliver therapeutic agents through skin and nails with the
`same efficacy as MediQuest TAM technology.
`
`2.    Vascana (Phase 3 Raynaud's phenomenon Drug; TAM + Nitroglycerin):
`MediQuest has a Special Protocol Assessment in place for the confirmatory trial needed to
`receive FDA approval for Raynaud's phenomenon. Raynaud’s patients can experience severe
`pain associated with chronic vasospasm episodes in their hands, feet and other extremities.
`Essentially, two options exist for the 2.1 million US patients seeking medical treatment. Patients
`can either take systemic medications designed to treat other conditions or modify their
`behavior in an attempt to subdue symptoms. MediQuest's therapy will potentially deliver relief
`through a safe topical formulation applied locally to prevent or treat Raynaud's episodes.
`
`http://www.prweb.com/releases/2012/9/prweb9911525.htm
`
`5/24/2016
`
`CFAD v. Anacor, IPR2015-01776 ANACOR EX. 2175 - 2/4
`
`

`
`MediQuest Announces Sale of Late Stage Onychomycosis Program to EFFELL LLC, Fir...
`
`Page 3 of 4
`
`3.    Skin Lighteners (Thioacetanilide); MediQuest has developed a treatment for people with
`hyperpigmented skin, age spots, liver spots, actinic damage. The market is believed to be
`several hundred million dollar currently in United States for an effective product.
`
`Disclaimer: In addition to historical facts or statements of current condition, this press release
`contains forward-looking statements within the meaning of the 'Safe Harbor' provisions of the
`Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the
`Company's current expectation or forecasts of future events. MediQuest's performance and
`financial results could differ materially from those reflected in these forward-looking
`statements due to the decisions of regulatory authorities, ability to implement its commercial
`plans, general financial, economic, regulatory and political conditions affecting the
`biotechnology and pharmaceutical industries generally. For a discussion of these and other
`risks and uncertainties that may affect the forward-looking statements please contact the
`Company. Given these risks and uncertainties, any or all of these forward-looking statements
`may prove to be incorrect. MediQuest undertakes no obligation to update publicly any forward-
`looking statement.
`
`Advisor and Contact: Joseph K. Piper, Managing Director, Point B Capital, 300 East Pine, Seattle,
`WA , 98122, 206.577.7223 jpiper(at)pointbcap(dot)com
`
`Share article on socal media or email:
`
`    
`
`View article via:
` PDF
` PRINT
`
`Contact Author
`
`JOSEPH PIPER
`
`206.577.7223
`Email >
`
`News Center
`
`PRWeb
`
`  
`
`http://www.prweb.com/releases/2012/9/prweb9911525.htm
`
`5/24/2016
`
`CFAD v. Anacor, IPR2015-01776 ANACOR EX. 2175 - 3/4
`
`

`
`MediQuest Announces Sale of Late Stage Onychomycosis Program to EFFELL LLC, Fir...
`
`Page 4 of 4
`
`Questions about a news article you've read?
`
`Reach out to the author: contact and available social following information is listed in the top-right
`of all news releases.
`
`Questions about your PRWeb account or interested in learning more about our news services?
`
`Call PRWeb:1-866-640-6397
`
`CREATE A FREE ACCOUNT
`
`©Copyright 1997-2015, Vocus PRW Holdings, LLC. Vocus, PRWeb, and Publicity Wire are trademarks or registered
`trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.
`
`http://www.prweb.com/releases/2012/9/prweb9911525.htm
`
`5/24/2016
`
`CFAD v. Anacor, IPR2015-01776 ANACOR EX. 2175 - 4/4